[go: up one dir, main page]

WO2000041681A3 - ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN - Google Patents

ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN Download PDF

Info

Publication number
WO2000041681A3
WO2000041681A3 PCT/EP2000/000318 EP0000318W WO0041681A3 WO 2000041681 A3 WO2000041681 A3 WO 2000041681A3 EP 0000318 W EP0000318 W EP 0000318W WO 0041681 A3 WO0041681 A3 WO 0041681A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
antagonist
formulations containing
medicinal formulations
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/000318
Other languages
English (en)
French (fr)
Other versions
WO2000041681A2 (de
Inventor
Johannes Bartholomaeus
Juergen Betzing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00901108A priority Critical patent/EP1143936A2/de
Priority to NZ513501A priority patent/NZ513501A/en
Priority to AU21090/00A priority patent/AU772886B2/en
Priority to SK1001-2001A priority patent/SK10012001A3/sk
Priority to JP2000593293A priority patent/JP2002534458A/ja
Priority to CA002359273A priority patent/CA2359273A1/en
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of WO2000041681A2 publication Critical patent/WO2000041681A2/de
Publication of WO2000041681A3 publication Critical patent/WO2000041681A3/de
Priority to NO20013302A priority patent/NO20013302D0/no
Priority to US09/907,447 priority patent/US20020044966A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft Arzneiformulierungen enthaltend ein Opioid, einen α-Agonisten und/oder jeweils dessen physiologisch verträgliches Salz, aus denen wenigstens ein Arzneimittelwirkstoff verzögert freigesetzt wird.
PCT/EP2000/000318 1999-01-18 2000-01-17 ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN Ceased WO2000041681A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ513501A NZ513501A (en) 1999-01-18 2000-01-17 Pharmaceutical formulations containing an opioid and an alpha-agonist
AU21090/00A AU772886B2 (en) 1999-01-18 2000-01-17 Medicinal formulations containing an opioid and an alpha-antagonist
SK1001-2001A SK10012001A3 (sk) 1999-01-18 2000-01-17 Farmaceutická formulácia obsahujúca opiát a alfa-agonistu
JP2000593293A JP2002534458A (ja) 1999-01-18 2000-01-17 オピオイド及びα−アゴニストを含有する薬剤
CA002359273A CA2359273A1 (en) 1999-01-18 2000-01-17 Pharmaceutical formulations containing an opioid and an .alpha.-agonist
EP00901108A EP1143936A2 (de) 1999-01-18 2000-01-17 ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN $g(a)-AGONISTEN
NO20013302A NO20013302D0 (no) 1999-01-18 2001-07-03 Medisinsk preparat inneholdende et opioid og en <alfa>- agonist
US09/907,447 US20020044966A1 (en) 1999-01-18 2001-07-18 Pharmaceutical formulations containing an opioid and an alpha-agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19901684.4 1999-01-18
DE19901684 1999-01-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/907,447 Continuation US20020044966A1 (en) 1999-01-18 2001-07-18 Pharmaceutical formulations containing an opioid and an alpha-agonist

Publications (2)

Publication Number Publication Date
WO2000041681A2 WO2000041681A2 (de) 2000-07-20
WO2000041681A3 true WO2000041681A3 (de) 2000-12-07

Family

ID=7894563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000318 Ceased WO2000041681A2 (de) 1999-01-18 2000-01-17 ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN

Country Status (15)

Country Link
US (1) US20020044966A1 (de)
EP (1) EP1143936A2 (de)
JP (1) JP2002534458A (de)
AR (1) AR022252A1 (de)
AU (1) AU772886B2 (de)
BR (1) BR0000578A (de)
CA (1) CA2359273A1 (de)
CO (1) CO5160243A1 (de)
HU (2) HU0000139D0 (de)
NO (2) NO20000225D0 (de)
NZ (1) NZ513501A (de)
PE (1) PE20001396A1 (de)
SK (1) SK10012001A3 (de)
UY (1) UY25936A1 (de)
WO (1) WO2000041681A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962019B2 (en) 2005-09-09 2015-02-24 Angelini Pharma, Inc. Sustained drug release composition

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2004509920A (ja) * 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
IL158819A0 (en) * 2001-05-31 2004-05-12 Skyepharma Inc Encapsulation of nanosuspensions in liposomes and microspheres
WO2003004032A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
US7485323B2 (en) * 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
WO2007016284A2 (en) * 2005-07-28 2007-02-08 Shire Llc Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
JP5269595B2 (ja) * 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
MX2009013384A (es) * 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica.
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
EP2265259A1 (de) * 2008-04-25 2010-12-29 Cadila Healthcare Limited Rasch im mund zerfallende zusammensetzungen aus tramadol
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
US8603497B2 (en) * 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
CA2784407A1 (en) * 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
RS56344B1 (sr) 2010-12-22 2017-12-29 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
BR112016006848A2 (pt) 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
TWI645866B (zh) 2013-10-07 2019-01-01 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN112494486B (zh) * 2020-12-07 2022-01-21 深圳善康医疗健康产业有限公司 一种用于减轻或消除阿片戒断综合症的药物组合物及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
PT99629A (pt) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Metodo de desintoxicacao de opiaceos
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
WO1999024023A2 (de) * 1997-11-11 1999-05-20 Grünenthal GmbH FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
PT99629A (pt) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Metodo de desintoxicacao de opiaceos
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
WO1999024023A2 (de) * 1997-11-11 1999-05-20 Grünenthal GmbH FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199325, Derwent World Patents Index; AN 1993-203390 [25], XP002143493 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962019B2 (en) 2005-09-09 2015-02-24 Angelini Pharma, Inc. Sustained drug release composition
US9439866B2 (en) 2005-09-09 2016-09-13 Angelini Pharma, Inc. Trazodone composition for once a day administration

Also Published As

Publication number Publication date
HU0000139D0 (en) 2000-03-28
AR022252A1 (es) 2002-09-04
NO20013302L (no) 2001-07-03
AU772886B2 (en) 2004-05-13
BR0000578A (pt) 2001-08-14
US20020044966A1 (en) 2002-04-18
AU2109000A (en) 2000-08-01
JP2002534458A (ja) 2002-10-15
EP1143936A2 (de) 2001-10-17
NZ513501A (en) 2003-11-28
NO20013302D0 (no) 2001-07-03
PE20001396A1 (es) 2000-12-23
NO20000225D0 (no) 2000-01-17
CO5160243A1 (es) 2002-05-30
CA2359273A1 (en) 2000-07-20
UY25936A1 (es) 2001-07-31
SK10012001A3 (sk) 2002-01-07
HUP0105043A3 (en) 2005-06-28
HUP0105043A2 (en) 2002-06-29
WO2000041681A2 (de) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
EP0839526A3 (de) Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
ZA200200743B (en) Preserved pharmaceutical formulations.
AU2300699A (en) Amidino derivatives and drugs containing the same as the active ingredient
AU1276501A (en) Active ingredient combination having insecticidal and acaricidal characteristics
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
MXPA03004941A (es) Formulacion farmacologica que tiene tolerancia por via oral mejorada.
AU2001234114A1 (en) Drugs containing combined active ingredients
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
MXPA01012478A (es) Formulaciones farmaceuticas mejoradas.
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
HUP0303673A3 (en) Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
MXPA02001575A (es) Agente farmaceutico que comprende un derivado de benzamida como un ingrediente activo.
ZA200304928B (en) Medicament containing a polyamine as an active substance.
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 21090/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000901108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006899

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 593293

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10012001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2359273

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2359273

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09907447

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 513501

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000901108

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000901108

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 21090/00

Country of ref document: AU